BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Urate Oxidase

Below is an extended Urate Oxidase research listing. Click here to return to the Urate Oxidase main in depth entry.

Recent Publications on Urate Oxidase:

Structures of Arthrobacter globiformis urate oxidase-ligand complexes.
The enzyme urate oxidase catalyzes the conversion of uric acid to...
Direct Link
1st October, 2008
Graduate School of Bioscience and Biotechnology, Tokyo Institute of
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Uricase is an important medical enzyme which can be used to determine...
Direct Link
23rd September, 2008
Laboratory of Yeast Molecular Genetics and Breeding, Institute of
Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Pegloticase is designed to convert urate into the easily excretable...
Direct Link
19th September, 2008
Universite de Montreal, Faculte de pharmacie, Pavillon Jean Coutu, 2940
Oxygen pressurized X-ray crystallography: probing the dioxygen binding site in cofactorless urate oxidase and implications for its catalytic mechanism.
The localization of dioxygen sites in oxygen-binding proteins is a...
Direct Link
17th September, 2008
CI-NAPS, UMR 6232-UCBN-CNRS-CEA, Centre Cyceron, 14074 Caen cedex, France.
Structural analysis of urate oxidase in complex with its natural substrate inhibited by cyanide: mechanistic implications.
BACKGROUND: Urate oxidase (EC 1.7.3.3 or UOX) catalyzes the conversion of...
Direct Link
16th September, 2008
LCRB, UMR CNRS 8015, Universite Paris Descartes, 4 avenue de
Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient.
Urate oxidase catalyzes the oxidation of uric acid with poor solubility to...
Direct Link
30th August, 2008
[The rasburicase therapy may cause hydrogen peroxide shock]
Hyperuricemia contributes to the pathomechanism of diseases such as renal...
Direct Link
19th August, 2008
Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. 11th July, 2008
West Virginia University School of Medicine, Robert C Byrd Health Sciences
Site-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coli.
Urate oxidase catalyzes the oxidation of uric acid with poor solubility to...
Direct Link
4th July, 2008
School of Life Science and Technology, China Pharmaceutical University,
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
AIMS: Hyperuricemia is a risk factor associated with cardiovascular and...
Direct Link
3rd July, 2008
Department of Nephrology, Dialysis and Hypertension, Malpighi Hospital,
SFCE (Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Rasburicase (Fasturtec), a recombinant urate oxidase, is highly effective...
Direct Link
5th June, 2008
Service d'Hematologie Pediatrie, Hopital Debrousse, Lyon, France.
[New antihyperuricemic medicine: febuxostat, Puricase, etc] 31st May, 2008
Department of Pathophysiology, Tokyo University of Pharmacy and Life
[How do we set the standard value of serum uric acid levels?] 31st May, 2008
Division of Molecular Medicine and Therapeutics, Tottori University,
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
INTRODUCTION: Oral fludarabine is the first oral formulation of a purine...
Direct Link
30th May, 2008
Department of Hematology, Hospital General de Lanzarote, Arrecife de
Refractory gout: what is it and what to do about it?
PURPOSE OF REVIEW: The purpose of this review is to discuss the defining...
Direct Link
30th April, 2008
Departments of Pediatrics, Duke University Medical Center, Durham, NC
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional